Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. (ABOS) is a clinical-stage biopharmaceutical company advancing sabirnetug (ACU193), an investigational monoclonal antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease. This page provides authorized news updates and press releases directly from the company and verified sources.
Key resources for stakeholders include updates on clinical trial progress, regulatory milestones, and strategic partnerships. All content is curated to meet investor needs for timely, accurate information on therapeutic developments and corporate announcements.
Regular updates cover clinical trial results, manufacturing advancements, scientific presentations, and financial disclosures. The news collection serves as a historical record of ABOS's progress in developing novel neurodegenerative disease treatments.
Bookmark this page for streamlined access to essential updates about Acumen's Alzheimer's research program and corporate developments. Check back regularly for new information directly affecting investment analysis and industry monitoring.
Acumen Pharmaceuticals (NASDAQ: ABOS) has announced the dosing of the first subject in a Phase 1 study of subcutaneous sabirnetug (ACU193) for early Alzheimer's disease. The study aims to compare the pharmacokinetics between subcutaneous and intravenous administrations in healthy volunteers. Sabirnetug, co-formulated with Halozyme's ENHANZE® technology, targets soluble amyloid beta oligomers (AβOs) in the brain.
The subcutaneous formulation is designed to provide a more convenient and accessible option for patients, potentially improving treatment adherence. Acumen is also currently conducting the ALTITUDE-AD Phase 2 trial to evaluate the efficacy and safety of intravenous sabirnetug in early AD patients. Previous Phase 1 results showed favorable safety, target engagement, and amyloid plaque reduction comparable to approved therapies.
Acumen Pharmaceuticals (NASDAQ: ABOS) presented new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference 2024. The research focuses on patient experiences, biomarker data, and a new ultra-sensitive assay for measuring sabirnetug in cerebrospinal fluid. Sabirnetug, a humanized monoclonal antibody, targets toxic soluble amyloid beta oligomers (AβOs) in early symptomatic Alzheimer's disease (AD).
Key findings include:
- Patient interviews revealed desires for treatments that slow disease progression and maintain cognitive abilities
- Sabirnetug significantly lowered CSF levels of synaptic proteins, supporting its mechanism of action
- A new ultra-sensitive assay was developed to detect sabirnetug in CSF
Acumen is currently conducting the Phase 2 ALTITUDE-AD trial to further evaluate sabirnetug's efficacy and safety in early AD patients.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC) 2024. The conference will be held in Philadelphia and online from July 28 to August 1, 2024. Sabirnetug, a humanized monoclonal antibody, has shown selective target engagement of toxic soluble amyloid beta oligomers (AβOs) in early symptomatic Alzheimer's disease (AD) patients. The company’s posters will discuss biomarker data, methods for detecting sabirnetug levels in cerebrospinal fluid (CSF), and patient experiences. The data aims to inform future clinical trials and potentially position sabirnetug as a best-in-class antibody treatment for early symptomatic AD.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported its Q1 2024 financial results and business highlights. The company announced the initiation of ALTITUDE-AD, a Phase 2 study of sabirnetug (ACU193) for early Alzheimer's disease, with the first patient dosed in May 2024. A Phase 1 study for a subcutaneous form of sabirnetug is expected in mid-2024. As of March 31, 2024, Acumen had $296.6 million in cash and equivalents, projected to fund operations into H1 2027. Financial results showed a net loss of $14.9 million, up from $11.3 million YoY. R&D expenses rose to $12.4 million from $8.7 million, while G&A expenses increased to $5.3 million from $4.4 million.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The company focuses on developing therapeutics targeting toxic soluble amyloid beta oligomers for treating Alzheimer's disease. The management will join a fireside chat scheduled for May 20, 2024, at 12:30 p.m. ET. The event will be available via a live webcast on the company's investor relations page, with an archive accessible for 90 days.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will participate in the 2024 Bank of America Healthcare Conference to discuss their novel therapeutic for treating Alzheimer's disease. The event will take place on May 15, 2024, and can be accessed via a live webcast on their website.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) has started the ALTITUDE-AD Phase 2 clinical trial of sabirnetug (ACU193) in early Alzheimer's Disease, representing a significant development in Alzheimer's research. This trial aims to evaluate the efficacy and safety of sabirnetug in patients with early AD, with promising Phase 1 results supporting its mechanism of action. The study will enroll approximately 540 patients with early AD and assess primary and secondary endpoints over 18 months.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will report first quarter 2024 financial results on May 14, 2024. The company is focused on developing a novel therapeutic for Alzheimer's disease. A conference call and webcast will be held to provide a business and financial update.
FAQ
What is the current stock price of Acumen Pharmaceuticals (ABOS)?
What is the market cap of Acumen Pharmaceuticals (ABOS)?
